Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Receivables (2016 - 2023)

Palisade Bio (PALI) has disclosed Receivables for 13 consecutive years, with $250000.0 as the latest value for Q1 2023.

  • On a quarterly basis, Receivables changed N/A to $250000.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $250000.0, a N/A change, with the full-year FY2022 number at $141250.0, changed N/A from a year prior.
  • Receivables was $250000.0 for Q1 2023 at Palisade Bio, up from $141250.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $466782.0 in Q1 2019 to a low of $21064.0 in Q4 2019.
  • A 5-year average of $222678.8 and a median of $246976.0 in 2020 define the central range for Receivables.
  • Peak YoY movement for Receivables: tumbled 94.12% in 2019, then soared 1267.26% in 2020.
  • Palisade Bio's Receivables stood at $21064.0 in 2019, then skyrocketed by 1267.26% to $288000.0 in 2020, then crashed by 79.51% to $59000.0 in 2021, then surged by 139.41% to $141250.0 in 2022, then soared by 76.99% to $250000.0 in 2023.
  • Per Business Quant, the three most recent readings for PALI's Receivables are $250000.0 (Q1 2023), $141250.0 (Q4 2022), and $59000.0 (Q2 2021).